Details : Endoxifen (z-endoxifen) is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Product Name : (Z)-Endoxifen
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 06, 2023
Details : Endoxifen (z-endoxifen) is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Product Name : (Z)-Endoxifen
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2023
Details : Under the agreement, Societal CDMO will provide a range of its Clinical Trial Services offerings focused on Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, the most active metabolite of the FDA approved SERM, tamoxifen...
Product Name : (Z)-Endoxifen
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 23, 2023
Details : (Z)-endoxifen is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Product Name : (Z)-Endoxifen
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 21, 2023
Atossa Therapeutics Shares Jump 35% Ahead of Data on Endoxifen in Breast Cancer Surgery Patients
Details : Endoxifen, an active metabolite of tamoxifen, which is an FDA-approved drug to treat ovarian and breast cancer. Endoxifen administered to breast cancer patients prior to surgery.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2021
Atossa Therapeutics Announces Findings from FDA-Approved Expanded Access Treatment with Endoxifen
Details : The study results show that treatment with Atossa’s proprietary Endoxifen for 20 days prior to unilateral mastectomy and for 18 months after surgery as an adjuvant did not lead to vasomotor symptoms commonly associated with tamoxifen.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 30, 2020
Atossa Therapeutics Announces Clinical Progress
Details : Completed treating a sufficient number of patients to permit an initial report of study results from the pilot portion of the study.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 04, 2020
Reset All
